HER2-Positive Breast Cancer

Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.

• Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive.

• Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations.

• Includes a timely section on innovative future therapies.

  Inhalt

  Background/testing 1. The HER2 alteration in breast cancer*

• 2. HER2 testing in the era of changing guidelines*
• Advanced Disease
  3. Optimal first-line treatment of HER2+ advanced disease*
• 4. Second line therapy and beyond*
• 5. HER2+ CNS metastases*

• Therapeutics

  6. Neoadjuvant therapy*
• 7. Adjuvant therapy*
• 8. Outcomes based on HR status in early stage disease*
• 9. De-escalation of therapy for small tumor*
• Toxicity considerations 10. Cardiac toxicity of HER2-targeted regimens*
• 11. Non-cardiac toxicity of HER2-targeted therapy*
• Therapies on the horizon 12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc)*
• 13. Harnessing the immune system in HER2+ disease*
• 14. Biosimilars